| Volume 1 | |||
| Innovative Antibiotics | |||
| Squarix GmbH becomes a consortional partner in the research network of university and industry within the North Rhine Westfalian Biotechnology Cluster “BioNRW” (InA Project). | |||
| Principal aims of the project |
|||
|
|||
Since the development of antibiotics, the improvement of hygienic standards and the beginning of vaccination programs life expectancy doubled between 1930 and 1990. Unfortunately multi resistant bacteria are undermining this progress. We find ourselves now at the beginning of an “antibiotic crisis”. Since decades it seemed that severe infections had been beaten, but even in the industrialized nations they are the third most common cause of death. Despite of this alarming trend many pharmaceutical companies have withdrawn themselves from R&D in the field of antibiotics. Together with 6 consortional partners in the research network of university and industry within the North Rhine Westfalian Biotechnology Cluster "BioNRW" we cover the whole value creation chain. Instead of a large research department we focus the different research expertise within one project. The remarkable thing about this collaboration is that we can bring a substance from initial laboratory testing on bacteria all the way to clinical testing. Squarix GmbH is providing the consortium with “small molecule” candidates derived from novel libraries. New antibacterial lead structures are tested microbiologically, pharmacologically and toxicologically. The subsequent preclinical and clinical development of different candidates will be performed within the consortium. |
|||
 Discovery Chemicals |
|
Custom Synthesis |
| Call us for a quote: +49-2365-20400-0 |
| Squarix GmbH Elbestraße 10 D-45768 Marl Germany |
| fon: +49-2365-20400-0 fax: +49-2365-20400-60 www.squarix.de e-mail: info@squarix.de |
|
Print newsletter (pdf format) |
| This project is sponsored by: |
 |
 |